ArticleBMC psychiatry2010
Predictors of switching antipsychotic medications in the treatment of schizophrenia.
Article in BMC psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.CNS drugs · 2025Pooled it
- Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia.The Cochrane database of systematic reviews · 2025Pooled it
- Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development.The lancet. Psychiatry · 2023Pooled it
- Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.BMC psychiatry · 2014Trial
- Assessment of psychotropic medicines utilization patterns for the treatment of mental and neurological disorders in Public Hospitals of Hadiya Zone, Southern Ethiopia: A record-based study.PLOS mental health · 2026Article
- Arabic translation and validation of the clinician administered Staden schizophrenia anxiety rating scale (S-SARS).Heliyon · 2024Article
- Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study.Journal of managed care & specialty pharmacy · 2024Observational
- Predictors of antipsychotics switching among ambulatory patients with schizophrenia in Ethiopia: a multicenter hospital-based cross-sectional study.Annals of general psychiatry · 2024Article
- Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).Journal of psychopharmacology (Oxford, England) · 2023Article
- Factors Influencing the Level of Depression and Anxiety of Community-Dwelling Patients with Schizophrenia in China during the COVID-19 Pandemic.International journal of environmental research and public health · 2023Article
- Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study.Journal of clinical medicine · 2022Article
- Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes.Neuropsychiatric disease and treatment · 2022Article
- Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil.Frontiers in pharmacology · 2021Article
- Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Article
- Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.BMC psychiatry · 2016Article
- Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.International clinical psychopharmacology · 2015Observational
- Review
- A retrospective study of antipsychotic drug switching in a pediatric population.BMC psychiatry · 2013Article
- Article
- Evidence review and clinical guidance for the use of ziprasidone in Canada.Annals of general psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.
methodsThis post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication.
resultsAbout one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.
conclusionsSwitching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.